Stock DNA
Pharmaceuticals & Biotechnology
CNY 11,176 Million (Large Cap)
20.00
NA
3.45%
-0.10
8.17%
1.64
Revenue and Profits:
Net Sales:
1,651 Million
(Quarterly Results - Jun 2025)
Net Profit:
169 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
7.27%
0%
7.27%
6 Months
-2.28%
0%
-2.28%
1 Year
-13.08%
0%
-13.08%
2 Years
-30.28%
0%
-30.28%
3 Years
6.79%
0%
6.79%
4 Years
6.31%
0%
6.31%
5 Years
-13.24%
0%
-13.24%
Zhejiang Conba Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0.38%
EBIT Growth (5y)
45.49%
EBIT to Interest (avg)
16.39
Debt to EBITDA (avg)
0.22
Net Debt to Equity (avg)
-0.04
Sales to Capital Employed (avg)
0.82
Tax Ratio
17.09%
Dividend Payout Ratio
60.90%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
8.79%
ROE (avg)
15.16%
Valuation key factors
Factor
Value
P/E Ratio
20
Industry P/E
Price to Book Value
1.64
EV to EBIT
20.83
EV to EBITDA
12.19
EV to Capital Employed
1.71
EV to Sales
1.65
PEG Ratio
NA
Dividend Yield
3.45%
ROCE (Latest)
8.23%
ROE (Latest)
8.17%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Bullish
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
1,651.50
1,662.20
-0.64%
Operating Profit (PBDIT) excl Other Income
228.20
256.10
-10.89%
Interest
1.70
2.30
-26.09%
Exceptional Items
16.10
18.90
-14.81%
Consolidate Net Profit
168.50
193.00
-12.69%
Operating Profit Margin (Excl OI)
85.40%
101.70%
-1.63%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -0.64% vs 5.02% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -12.69% vs 72.01% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
6,435.60
6,647.80
-3.19%
Operating Profit (PBDIT) excl Other Income
907.20
1,014.00
-10.53%
Interest
21.80
37.40
-41.71%
Exceptional Items
29.70
-151.70
119.58%
Consolidate Net Profit
658.40
674.70
-2.42%
Operating Profit Margin (Excl OI)
86.00%
102.40%
-1.64%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -3.19% vs 12.18% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -2.42% vs 46.64% in Dec 2023
About Zhejiang Conba Pharmaceutical Co., Ltd. 
Zhejiang Conba Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






